Michael Barbella, Managing Editor06.17.22
Impulse Dynamics' Optimizer Smart Mini has been implanted for the first time by doctors at two different U.S. institutions.
“We’re excited to be one of the first institutions to implant this latest generation CCM therapy device,” said Dr. Ameer Kabour, an interventional cardiologist and director of Cardiology at Mercy Health St. Vincent Medical Center in Toledo, Ohio. “The Optimizer Smart Mini provides convenience to both providers and many of their patients who suffer from heart failure. These patients may be suffering in spite of being on medications. This device can help relieve many of these patients’ symptoms in the short term, and the diagnostics it provides can help us manage their disease over the long term.”
“In the ambulatory surgical center setting, we strive to make our patients’ experiences as simple, safe, and effective as possible,” said Andrew Kaplan, M.D., a clinical cardiac electrophysiologist with Southwest Cardiovascular Associates in Mesa, Ariz. “The reduced size, physiologic shape, and simplified programming that this new generation of device offers can help us meet all of those requirements.”
The Optimizer Smart Mini incorporates a rechargeable battery with 20-year battery life, offering HF diagnostic monitoring that provides important clinical insights to providers to assist in managing their patients with heart failure. This latest generation also offers new internal technology with improved programming and a smaller size designed to make the implant procedure faster and easier for patients and physicians.
“We are committed to continued innovation by not only including a 20-year battery but by also making this new device 25 percent smaller and 33 percent lighter than its predecessor. Over 7,000 patients have now benefitted from our CCM therapy,” said Jason Spees, president and chief commercial officer at Impulse Dynamics. “It is great to know that the millions of patients that could benefit from our CCM therapy worldwide will now get an even better device.”
The Optimizer Smart Mini delivers CCM therapy to the heart. CCM therapy delivers precisely timed electrical pulses to the heart that are intended to improve the heart’s ability to contract, allowing more oxygen-rich blood to be pushed out through the body.1 CCM therapy is indicated to improve six-minute hall walk, quality of life, and functional status of NYHA (New York Heart Association) Class III heart failure patients who remain symptomatic despite guideline-directed medical therapy, are not indicated for CRT(cardiac resynchronization therapy), and have a left ventricular ejection fraction ranging from 25 to 45 percent.
Marlton, N.J.-based Impulse Dynamics has pioneered CCM therapy, which is delivered by the Optimizer Smart Mini, a U.S. Food and Drug Administration-approved treatment verified to improve the quality of life for certain heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them.
Reference
1 European Journal of Heart Failure (2021) doi:10.1002/ejhf.2202
“We’re excited to be one of the first institutions to implant this latest generation CCM therapy device,” said Dr. Ameer Kabour, an interventional cardiologist and director of Cardiology at Mercy Health St. Vincent Medical Center in Toledo, Ohio. “The Optimizer Smart Mini provides convenience to both providers and many of their patients who suffer from heart failure. These patients may be suffering in spite of being on medications. This device can help relieve many of these patients’ symptoms in the short term, and the diagnostics it provides can help us manage their disease over the long term.”
“In the ambulatory surgical center setting, we strive to make our patients’ experiences as simple, safe, and effective as possible,” said Andrew Kaplan, M.D., a clinical cardiac electrophysiologist with Southwest Cardiovascular Associates in Mesa, Ariz. “The reduced size, physiologic shape, and simplified programming that this new generation of device offers can help us meet all of those requirements.”
The Optimizer Smart Mini incorporates a rechargeable battery with 20-year battery life, offering HF diagnostic monitoring that provides important clinical insights to providers to assist in managing their patients with heart failure. This latest generation also offers new internal technology with improved programming and a smaller size designed to make the implant procedure faster and easier for patients and physicians.
“We are committed to continued innovation by not only including a 20-year battery but by also making this new device 25 percent smaller and 33 percent lighter than its predecessor. Over 7,000 patients have now benefitted from our CCM therapy,” said Jason Spees, president and chief commercial officer at Impulse Dynamics. “It is great to know that the millions of patients that could benefit from our CCM therapy worldwide will now get an even better device.”
The Optimizer Smart Mini delivers CCM therapy to the heart. CCM therapy delivers precisely timed electrical pulses to the heart that are intended to improve the heart’s ability to contract, allowing more oxygen-rich blood to be pushed out through the body.1 CCM therapy is indicated to improve six-minute hall walk, quality of life, and functional status of NYHA (New York Heart Association) Class III heart failure patients who remain symptomatic despite guideline-directed medical therapy, are not indicated for CRT(cardiac resynchronization therapy), and have a left ventricular ejection fraction ranging from 25 to 45 percent.
Marlton, N.J.-based Impulse Dynamics has pioneered CCM therapy, which is delivered by the Optimizer Smart Mini, a U.S. Food and Drug Administration-approved treatment verified to improve the quality of life for certain heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them.
Reference
1 European Journal of Heart Failure (2021) doi:10.1002/ejhf.2202